L Liberti

Summary

Publications

  1. ncbi Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process
    L Liberti
    Centre for Medicines Research International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 87:27-31. 2010
  2. ncbi Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment
    S Walker
    CMR International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 85:241-6. 2009
  3. ncbi Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters
    S Walker
    CMR International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 89:179-82. 2011

Collaborators

Detail Information

Publications3

  1. ncbi Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process
    L Liberti
    Centre for Medicines Research International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 87:27-31. 2010
    ....
  2. ncbi Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment
    S Walker
    CMR International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 85:241-6. 2009
    ....
  3. ncbi Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters
    S Walker
    CMR International Institute for Regulatory Science, London, UK
    Clin Pharmacol Ther 89:179-82. 2011
    ..Building on prior experiences with a validated framework approach, this forum focused on identifying challenges and approaches to the assignment of values and weightings using a case study applied to a hypothetical medicinal product...